trending Market Intelligence /marketintelligence/en/news-insights/trending/t0fsd69hdqx8j_-knqh6a2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Gates Foundation to advance HIV prevention with $140M investment

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency

Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration

State of South Korean OTT Video: Subscription

Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook


Gates Foundation to advance HIV prevention with $140M investment

The Bill & Melinda Gates Foundation is investing up to $140 million in Intarcia Therapeutics Inc. as part of an effort to combat HIV.

Intarcia Therapeutics is developing an anti-HIV vaccine that would be administered annually or semi-annually in sub-Saharan Africa and other countries where the epidemic is most severe.

The company attracted funding from the Gates Foundation during its second series EE equity financing which yielded $206 million in proceeds.

The Gates Foundation committed $50 million during the financing and has agreed to pay up to a further $90 million in milestone-related payments to the HIV vaccination.